Duodenal ulcers recur within a year in 80-90% of patients treated initially with H2 antagonists,'-' and evidence now exists that relapse rates may be lower after treatment with other ulcer healing drugs. Moshal postulated in 1978 that relapse rates might be lower after treatment with tripotassium di-citrato bismuthate (Moshal MG, Sixth World Congress of Gastroenterology, Madrid, 1978), and in a double blind prospective study we showed that this was indeed so.9 McLean and others'" have concluded that this may also be true for other ulcer healing drugs, including antacids," anticholinergics,'2 antacid and anticholinergic combinations,'3 carbenoxolone,'4 1 ' sucralfate,'6 and trithiozine. 17 18
important implications. Using life table analysis, however, probably underestimates the real difference between the treatments in terms of morbidity, time, and cost because patients who relapse are not (usually) dead. They are simply withdrawn from the trial and require further treatment, which will often be another course of drugs or some form of maintenance. Maintenance treatment is effective28 but because of the cost is likely to be reserved for patients who relapse rapidly and predictably and for certain high risk groups.
We have applied an analysis similar to that of McLean and others'0 to the data from the six studies921-25 and calculated the relapse rates after healing with an H2 antagonist (17% a month) and with tri-potassium di-citrato bismuthate (7% a month). Using these rates we have investigated the implications of a policy of repeated courses of treatment with the same agent-either an H2 antagonist or tri-potassium dicitrato bismuthate-when a patient relapses. After a short time a steady state is reached in which 19% of the H2 antagonist group are on treatment but only 10% of the tripotassium di-citrato bismuthate group. Twice as much H2 antagonist will thus be used, which would double the costs with cimetidine and triple them with ranitidine at current non-contract prices. Furthermore, at any time more patients on H2 antagonists have an ulcer, although they will not necessarily be symptomatic.
This model may not reflect accurately clinical practice and may apply more to the artificial context of the clinical trial. Nevertheless, it probably gives a better idea of clinical practice than the usual life table analysis. Outside clinical trials patients who undergo asymptomatic relapse are unlikely to be diagnosed or treated. This will reduce the overall costs of drug treatment, but the differential costs may still apply unless asymptomatic relapse is much less common after tri-potassium di-citrato bismuthate than after an H2 antagonist.
The reason for the difference in relapse rates is unknown. The notion that H2 antagonists heal more "difficult" ulcers that are also more prone to relapse29 is not tenable since the healing rates in the six studies were actually slightly higher with tri-potassium di-citrato bismuthate than with the H2 antagonists. Rapid relapse after an H2 antagonist might be explained by rebound hypersecretion secondary to previous suppression of acid secretion leading to hypergastrinaemia and increased parietal cell mass. Although increases in serum BRITISH MEDICAL JOURNAL VOLUME 293 1 NOVEMBER 1986 gastrin concentration during treatment with H2 antagonists have often been reported, there is little evidence of rebound hypersecretion and increased parietal cell mass. 30 Recently, however, increased sensitivity of the parietal cell after ranitidine treatment to the submaximal and more physiological stimulus of simulated feeding has been reported.3'
The difference in relapse rates may relate to the duodenal mucosal cell failing to return to normal after an H2 antagonist but not after tri-potassium di-citrato bismuthate.Y --This requires confirmation, and even if true the mechanism remains to be determined. The relation between Campylobacter pyloridis, gastritis, and peptic ulceration might be relevant.33 Tri-potassium di-citrato bismuthate seems to remove Campylobacter pyloridis from gastric mucus whereas H2 antagonists do not. I A further suggestion35 is that because of accumulation within the body bismuth continues to be excreted after tri-potassiuim di-citrato bismuthate is stopped.3' If correct this would imply a systemic and not just a local effect on ulcer healing. It also raises the spectre of bismuth encephalopathy, but this has not been reported with tri-potassium di-citrato bismuthate, which is recommended for four to eight week courses to heal ulcers and not for prolonged maintenance.
The higher relapse rates after healing with H2 antagonists compared with tr-potassium di-citrato bismuthate (and perhaps other agents) is now well established and should probably influence prescribing. Furthermore, a large scale trial to test the predictions of our model seems worth while. We are grateful to Professor G Bianchi Porro for allowing us to use his full data currently being prepared for publication.
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